Transcatheter aortic valve replacement (TAVR) has emerged as the treatment of choice among inoperable patients with symptomatic severe aortic stenosis and as a treatment alternative to surgical aortic valve replacement (SAVR) for high-risk surgical patients [1] [2] [3] . Subsequently, the number of patients undergoing TAVR worldwide is steadily increasing and the complications related to valve implantation have been well-recognised.
. In this analysis, non-coronary aortic cusp thickness was the strongest predictor (P=0.002, correlation coefficient =0.655). A similar study by Baan et al. 8 found in 34 MCP patients that small left-ventricular outflow tract diameter, left axis deviation, significant mitral annular calcification and lower post-implant valve area are predicting post-TAVR PPM. Several studies showed that right bundle-branch block (RBBB) at baseline is one of the most significant predictors of PPM after TAVR [9] [10] [11] [12] [13] [14] . Additionally, baseline first-degree atrioventricular (AV) block 10 , left anterior hemiblock 12 and intraprocedural AV block 15 are important predictors for PPM dependence. Most of the previously mentioned studies looked at a low number of cases. In contrast to the recent meta-analysis of Siontis et al., RBBB (n=2158; risk ratio (RR): 2.89 (CI: 2.36-2.54), p<0.01), baseline AV block (n=1381; RR: 1.52 (CI: 1.15-2.01), p<0.01), and left anterior hemiblock (n=1065; RR: 1.62 (CI: 1.17-2.25), p<0.01) were the strongest predisposing conduction disturbances for PPM 16 . Figure 1 emphasises the close anatomical relationship of the cardiac conduction system referring to the aortic valve and highlights the importance of pre-existing conduction abnormalities as a predictor for PPM after TAVR.
Abstract
The number of patients undergoing transcatheter aortic valve replacement (TAVR) worldwide is increasing steadily. Atrioventricular conduction disturbances, with or without the need for permanent pacemaker (PPM) implantation, are one of the most common adverse events after TAVR. Among transcatheter heart valves (THV), rates of conduction abnormalities vary from less than 10 % to more than 50 %. Depending on the reported data referred to, historical data showed that up to one-third of the patients required implantation of a PPM following TAVR. Although generally considered as a minor complication, PPM may have a profound impact on prognosis and quality of life after TAVR. Current data support the hypothesis that conduction abnormalities leading to pacemaker dependency result from mechanical compression of the conduction system by the prosthesis stent frame and individual predisposing conduction defects such as right bundle-branch block (RBBB). With several large randomised trials and registry studies having been published recently and second generation THV having been introduced, the debate about predictors for pacemaker implantation and their impact on outcome after TAVR is still ongoing.
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Prosthesis Type and Time of PPM

Prosthesis Type
The incidence of AV conduction disturbances as a result of TAVR and the subsequent requirement for permanent pacing differs between the two most widely used bioprostheses, the balloon-expandable which was a prospective, single-arm, multicentre study showed a PPM rate of 28.6 % at 30 days 24 , which might be explained by the fact that all patients with borderline aortic annulus had to undergo TAVR with the larger 27 mm prosthesis, since the 25 mm prosthesis was not available at that time. The exact time point for PPM implantation is still an ongoing debate.
Another aspect, which has to be kept in mind, is the fact that selfexpanding prostheses may lead to delayed injuries of the conduction system. So far, there is no explicit data for the best time point for PPM implantation in patients after Boston Lotus, Medtronic engager or Jena valve implantation.
Pre-and Post-dilatation and Prosthesis Sizing
The close relationship of the conduction system to the aortic annulus may lead to a mechanical interaction between the prosthesis stent frame of the transcatheter valve prosthesis and the left bundlebranch, which in turn may translate into the occurrence of an LBBB and eventually into a higher grade or complete atrio-ventricular block.
A study by Lange et al. 31 analysed the impact of valvuloplasty balloon catheter size on the need for PPM in a larger cohort of 237 patients without prior pacemaker, who underwent TAVR with the MCP. In this analysis, the overall incidence of PPM was 21.1 %, but was significantly higher when a 25 mm balloon was used (27.1 %) than when a 23 mm These results suggest that pacemaker rates after TAVR may be reduced by using undersized BAV balloons or even avoidance of predilation. Two randomised studies are currently ongoing to investigate direct TAVR without pre-dilatation with the MCP (SIMPLIFY TAVI Trial; NCT01539746) and the ESV (EASE-IT Trial; NCT02127580). Interestingly, in another study post-dilation after MCP, implantation had no effect on the requirement for PPM. The reason for this observation might be the relatively short time period when the aortic annulus is exposed to high pressure from repeated valvuloplasty 31 . Post-dilatation after ESV TAVR ranges between 20-41 % 32-34 and shows no impact on PPM rate. A recent analysis showed a low post-dilatation rate of 4 % after Edwards SAPIEN 3 TAVR 33 .
The degree of prosthesis oversizing may lead to a higher incidence of PPM. Schroeter et al. found larger or significantly oversized prostheses to be an independent risk factor for PPM implantation following TAVR with the MCP 35 . In contrast, a study of Binder et al. with 89 patients receiving a SAPIEN XT THV showed that annular area oversizing was not associated with new conduction disturbances and permanent pacemaker implantation 36 . If this difference can be explained by the fact that the ESV prosthesis is oversized to a lesser degree to prevent annulus rupture remains unclear and needs further investigation.
Implantation Depths and Approach
Many studies have shown that the CoreValve prosthesis implantation depth is a predictor for PPM. The deeper the CoreValve frame protrudes into the left ventricular outflow tract, the more likely the patient is to develop an LBBB. In an early study by Piazza et al. 37 , the mean implantation depth was 10.3 mm in those patients with new LBBB versus 5.5 mm in those without LBBB. Another study proposed a cutoff of 6.0 mm as an independent predictor of the development of a high-degree AV block and the requirement for permanent pacing 29 . This finding was confirmed for the MCP prosthesis by several other recently published studies 8, 38, 39, 12 . Additionally, implantation of balloonexpandable transfemoral THVs with increased implantation depth is associated with clinically significant new conduction disturbances and permanent pacemaker implantation 36 . These effects also apply to ESV implantation via a transapical approach 40 .
The PPM incidence regarding TAVR approach is difficult to assess because patient population and risk profile are often different. A recent meta-analysis of Siontis et al. 16 suggested a trend towards lower risk of PPM after MCP TAVR with the transfemoral approach compared with the transsubclavian approach (p=0.07). The same meta-analysis found no difference in PPM risk after ESV TAVR depending on the approach (transapical versus transfemoral; n=2136; risk ratio: 0.89, 95 % CI: 0.64-1.25; p=0.89).
Cost and Outcome of PPM Implantation
Cost
Patients with AV conduction disturbances after TAVR are disposed to prolonged hospitalisation and use of in-hospital continuous telemetry 43 , both of which result in a considerable increase of overall cost of the TAVR procedure. Data from the FRANCE registry found that receiving a pacemaker was associated with a 36 % increase in cost 44 . Gutmann et al. assessed elevated procedural costs of €1,946 in case of PPM implantation in a German healthcare analysis 45 . Compared with surgical aortic valve replacement (SAVR), in-hospital costs were higher in TAVR patients than in SAVR patients (€40,802 versus €33,354, respectively; p=0.010) 46 ). Reducing PPM rate would have an impact on the cost-effectiveness of TAVR relative to that of SAVR.
Outcome
The impact of new-onset LBBB, with or without need for PPM implantation, on patient outcome after TAVR is still under debate.
Houthuizen et al. found negative effects of a procedure-related LBBB on survival in a group of 679 patients after TAVR. They described an all-cause mortality of 37.8 % (n=88) in 233 patients with new-onset as compared with those with LBBB during 12 months of follow-up (51±12 %; p=0.052), but found no difference in clinical outcome 52 . These findings were confirmed by Nazif et al. who presented the one-year results of the PARTNER trial and focused on new-onset LBBB which was not associated with significant differences in one-year mortality, cardiovascular mortality or repeat hospitalisation.
However, it was associated with increased PPM implantation during hospitalisation (8.3 % versus 2.8 %, p=0.005) and the ejection fraction failed to improve after TAVR in patients with new LBBB and remained lower at six months to one year (52.8 % versus 58.1 %, p=0.001) 53 . The independent predictors of the outcome in patients with new-onset LBBB (including the protective or detrimental effect of pacemaker implantation after TAVR) are currently unclear and still need further investigation.
Clinical Implication
Temporarily inserted pacing leads are mandatory for rapid pacing during the procedure as well for at least 24 hours after TAVR for therapy of delayed bradycardia. Patients with self-expanding valves like the MCP should be monitored for at least 48 hours after TAVR 54 . In case of new-onset LBBB or AV block, ECG monitoring should be continued for five days. In particular, those patients with pre-existing conduction disturbances such as RBBB or first-degree AV block should be carefully monitored with daily ECG. Pacemaker rates after TAVR may be safely decreased by avoiding pre-dilatation or use of undersized balloons 31 , as well as correct positioning of the prosthesis 37 .
Future Considerations
Increasing data from observational studies involving new valve PPM rate is important, especially as TAVR technology could be increasingly applied to younger and healthier patients. n
